These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 8580814)

  • 21. [Efficacy and survival analysis of DICE regimen for 97 patients with relapsed or refractory Non-Hodgkin's lymphoma].
    Ping LY; Song YQ; Zheng W; Wang XP; Xie Y; Lin NJ; Tu MF; Ying ZT; Liu WP; Zhang C; Deng LJ; Zhu J
    Zhonghua Xue Ye Xue Za Zhi; 2016 Sep; 37(9):790-794. PubMed ID: 27719723
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
    Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Results of a salvage regimen in refractory or relapsed non-Hodgkin's lymphoma.
    Buzzoni R; Colleoni M; Nelli P; Nolè F; Bajetta E
    Leuk Lymphoma; 1994 Jun; 14(1-2):121-8. PubMed ID: 7920218
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ifosfamide, mitoxantrone and etoposide (VIM) as salvage therapy of low toxicity in non-Hodgkin's lymphoma.
    Hopfinger G; Heinz R; Koller E; Schneider B; Pittermann E
    Eur J Haematol; 1995 Oct; 55(4):223-7. PubMed ID: 7589338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
    Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.
    Biagi JJ; Herbert KE; Smith C; Abdi E; Leahy M; Falkson C; Wolf M; Januszewicz H; Seymour JF; Richards K; Matthews JP; Dale B; Prince HM
    Leuk Lymphoma; 2005 Feb; 46(2):197-206. PubMed ID: 15621802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged daily administration of oral etoposide in lymphoma following prior therapy with adriamycin, an ifosfamide-containing salvage combination, and intravenous etoposide.
    Haim N; Ben-Shahar M; Epelbaum R
    Cancer Chemother Pharmacol; 1995; 36(4):352-5. PubMed ID: 7543029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
    Garay G; Dupont J; Dragosky M; Nucifora E; Cacchione R; Schnidrig P; Fernández J; Abel-Alzueta ; Riveros D; Noviello V; Bèguelin R; Campestri R; Albera C; Nicastro M; Triguboff E
    Leuk Lymphoma; 1997 Aug; 26(5-6):595-602. PubMed ID: 9389366
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DIZE (dexamethasone, idarubicin, and continuous infusion of ifosfamide and etoposide): an effective and well-tolerated new regimen for patients with relapsed lymphoma.
    Reiser M; Schnell R; Straub G; Borchmann P; Wilhelm M; Ubelacker R; Wörmann B; Münch R; Diehl V; Engert A
    Leuk Lymphoma; 1998 Oct; 31(3-4):359-66. PubMed ID: 9869200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Efficacy of DICE (dexamethasone, etoposide, ifosfamide, and cisplatin) regimen on recurrent and refractory non-Hodgkin's lymphoma].
    Bo LJ; Liang AB; Liu B; Chen YH; Wang F; Jin XP
    Ai Zheng; 2006 Dec; 25(12):1553-6. PubMed ID: 17166385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912.
    Kobrinsky NL; Sposto R; Shah NR; Anderson JR; DeLaat C; Morse M; Warkentin P; Gilchrist GS; Cohen MD; Shina D; Meadows AT
    J Clin Oncol; 2001 May; 19(9):2390-6. PubMed ID: 11331317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ESHAP as salvage therapy for refractory non-Hodgkin's lymphoma: Taiwan experience.
    Wang WS; Chiou TJ; Liu JH; Fan FS; Yen CC; Tung SL; Chen PM
    Jpn J Clin Oncol; 1999 Jan; 29(1):33-7. PubMed ID: 10073149
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for non-Hodgkin's lymphomas: a Swedish national prospective study. Swedish Lymphoma Study Group.
    Enblad G; Hagberg H; Glimelius B
    Acta Oncol; 1996; 35(2):165-70. PubMed ID: 8639311
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma.
    Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K
    Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Etoposide, ifosfamide, and methotrexate combination chemotherapy for aggressive non-Hodgkin's lymphomas after failure of the LNH 84 regimen.
    Herbrecht R; Damonte JC; Dufour P; Maloisel F; Liu KL; Ortiz S; Bergerat JP; Oberling F
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):7-10. PubMed ID: 1384135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ifosfamide, cisplatin, and etoposide (ICE) in the treatment of advanced non-small cell lung cancer.
    Shepherd FA; Evans WK; Goss PE; Latreille J; Logan D; Maroun J; Stewart D; Warner E; Paul K
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):54-8. PubMed ID: 1329213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase II study of ifosfamide in combination with etoposide and cisplatin in the treatment of extensive small cell lung cancer.
    Evans WK; Stewart D; Logan D; Maroun J; Goss G; Shepherd FA; Latreille J; Warner E; Dahrouge S
    Semin Oncol; 1992 Dec; 19(6 Suppl 12):51-6. PubMed ID: 1336622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.